S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$1.52
-0.05 (-3.18 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.46
Now: $1.52
$1.60
50-Day Range
$1.35
MA: $1.90
$2.22
52-Week Range
$0.25
Now: $1.52
$2.47
Volume1.30 million shs
Average Volume5.97 million shs
Market Capitalization$127.09 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Aileron Therapeutics logo

Headlines

Aileron Pops on Cusp of Cancer Drug Tests
January 5, 2021 |  baystreet.ca
Is Aileron Therapeutics, Inc. (ALRN) A Good Stock To Buy?
November 29, 2020 |  finance.yahoo.com
New Strong Sell Stocks for November 24th
November 24, 2020 |  finance.yahoo.com
Why Aileron's Stock Is Trading Lower Today
October 26, 2020 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900
Employees13
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.58 per share

Profitability

Net Income$-29,370,000.00

Miscellaneous

Market Cap$127.09 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

259th out of 1,962 stocks

Pharmaceutical Preparations Industry

123rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$1.52
-0.05 (-3.18 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aileron Therapeutics?

Wall Street analysts have given Aileron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aileron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decrease in short interest during the month of January. As of January 29th, there was short interest totaling 1,270,000 shares, a decrease of 28.2% from the January 14th total of 1,770,000 shares. Based on an average daily volume of 3,530,000 shares, the days-to-cover ratio is presently 0.4 days.
View Aileron Therapeutics' Short Interest
.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings data on Tuesday, November, 17th. The company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.13).
View Aileron Therapeutics' earnings history
.

How has Aileron Therapeutics' stock price been impacted by Coronavirus?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALRN stock has increased by 277.1% and is now trading at $1.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALRN?

3 analysts have issued 1 year price targets for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they anticipate Aileron Therapeutics' stock price to reach $3.50 in the next year. This suggests a possible upside of 130.3% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 51, Pay $580.43k)
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 48, Pay $331.19k)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 54, Pay $411.19k)
  • Mr. Richard J. Wanstall M.B.A., SVP, CFO & Treasurer (Age 52)

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Satter Management CO. L.P. (9.10%), Renaissance Technologies LLC (0.76%), Blair William & Co. IL (0.32%), GSA Capital Partners LLP (0.20%), Game Plan Financial Advisors LLC (0.16%) and Kestra Advisory Services LLC (0.07%). Company insiders that own Aileron Therapeutics stock include Bioventures Ltd Novartis, Jeffrey Allen Bailey, Kathryn Gregory, Muneer A Satter, Reinhard J Ambros, Rickenbach Josef H Von and Vojo Vukovic.
View institutional ownership trends for Aileron Therapeutics
.

Which institutional investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Aileron Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Aileron Therapeutics stock?

ALRN stock was bought by a variety of institutional investors in the last quarter, including Satter Management CO. L.P., GSA Capital Partners LLP, Game Plan Financial Advisors LLC, Kestra Advisory Services LLC, and Blair William & Co. IL. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Kathryn Gregory, Muneer A Satter, Reinhard J Ambros, Rickenbach Josef H Von, and Vojo Vukovic.
View insider buying and selling activity for Aileron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.52.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $127.09 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 13 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

Where are Aileron Therapeutics' headquarters?

Aileron Therapeutics is headquartered at 490 Arsenal Way, Watertown MA, 02472.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.